A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases. (PH-MPD1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01884974|
Recruitment Status : Unknown
Verified June 2015 by Shoshan Perek, Carmel Medical Center.
Recruitment status was: Recruiting
First Posted : June 24, 2013
Last Update Posted : June 16, 2015
Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.
The purpose of this research:
- Assess Prevalence of PH in patients with CMPD in Northern Israel
- Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.
|Condition or disease||Intervention/treatment|
|Myeloproliferative Disease Pulmonary Hypertension||Other: myeloproliferative disease|
study will include the following:
- age diagnosed with Myeloproliferative disease
- clinical manifestations of the myeloproliferative disease
- JAK2 mutation
- known hematological complications
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Observational Model:||Case Control|
|Official Title:||A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||June 2016|
Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
Other: myeloproliferative disease
Echocardiogram, demographic data, St George respiratory questioner
- pulmonary hypertension [ Time Frame: 1 year ]all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.
- St George Respiratory Questionnaire [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01884974
|Contact: Shoshan Perek, MDfirstname.lastname@example.org|
|Pulmonology Institute, Carmel Medical Center||Recruiting|
|Haifa, Israel, 34632|
|Contact: Shoshan Perek, MD 972-4-8250517|
|Principal Investigator: Shoshan Perek, MD|
|Principal Investigator:||Shoshan Perek, MD||Carmel Medical Center|